PMC:7696151 / 5960-6862 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"162","span":{"begin":577,"end":580},"obj":"Species"},{"id":"163","span":{"begin":406,"end":409},"obj":"Chemical"},{"id":"164","span":{"begin":489,"end":492},"obj":"Chemical"},{"id":"165","span":{"begin":460,"end":468},"obj":"Disease"},{"id":"166","span":{"begin":565,"end":575},"obj":"Disease"},{"id":"167","span":{"begin":585,"end":593},"obj":"Disease"}],"attributes":[{"id":"A162","pred":"tao:has_database_id","subj":"162","obj":"Tax:12721"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"MESH:D006886"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"MESH:D006886"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"MESH:C000657245"},{"id":"A166","pred":"tao:has_database_id","subj":"166","obj":"MESH:D007239"},{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In our review, the articles included were also analyzed in relation to the year of publication and the experimental model used. Regarding the chronology of the publications, most of the articles were published in the last decade. The high peaks correspond to the proportional number of papers on antiviral activity in 2020; this result is consistent with the actual increasing interest towards the role of HCQ as a possible therapeutic strategy in the current COVID-19 sanitary emergency. HCQ alone, or in combination with other drugs, was used in various types of infections. HIV and COVID-19 were the most cited, with 10 and 7 reports each, respectively. Our systematic review included 49 preclinical studies and 84 clinical trials. The considered in vivo studies were carried out using allograft or xenograft models. The most important outcomes of the review are graphically illustrated in Figure 3."}

{"project":"LitCovid-sentences","denotations":[{"id":"T51","span":{"begin":0,"end":127},"obj":"Sentence"},{"id":"T52","span":{"begin":128,"end":229},"obj":"Sentence"},{"id":"T53","span":{"begin":230,"end":488},"obj":"Sentence"},{"id":"T54","span":{"begin":489,"end":576},"obj":"Sentence"},{"id":"T55","span":{"begin":577,"end":656},"obj":"Sentence"},{"id":"T56","span":{"begin":657,"end":734},"obj":"Sentence"},{"id":"T57","span":{"begin":735,"end":819},"obj":"Sentence"},{"id":"T58","span":{"begin":820,"end":902},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In our review, the articles included were also analyzed in relation to the year of publication and the experimental model used. Regarding the chronology of the publications, most of the articles were published in the last decade. The high peaks correspond to the proportional number of papers on antiviral activity in 2020; this result is consistent with the actual increasing interest towards the role of HCQ as a possible therapeutic strategy in the current COVID-19 sanitary emergency. HCQ alone, or in combination with other drugs, was used in various types of infections. HIV and COVID-19 were the most cited, with 10 and 7 reports each, respectively. Our systematic review included 49 preclinical studies and 84 clinical trials. The considered in vivo studies were carried out using allograft or xenograft models. The most important outcomes of the review are graphically illustrated in Figure 3."}